Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
NKTR-262 is small molecule that targets the Toll-like receptor 7/8 pathway, triggering an innate immune response and the release of tumor antigens, which potentially leads to tumor regression when combined with a checkpoint inhibitor (Journal for ImmunoTherapy of Cancer 2017, 5 (Suppl 2):87 #P275).
|Therapy Name||Drugs||Efficacy Evidence||Clinical Trials|
|Nivolumab + NKTR-214 + NKTR-262||NKTR-214 NKTR-262 Nivolumab||0||1|
|NKTR-214 + NKTR-262||NKTR-214 NKTR-262||0||1|